What poractant alfa bronchiolitis trials are listed on ClinicalTrials.gov?
ClinicalTrials.gov has searched and trial listings for poractant alfa in different pediatric and lung-disease settings, but a “bronchiolitis” search specifically can return no exact matches depending on how the condition is coded (for example, “bronchiolitis,” “acute bronchiolitis,” “RSV bronchiolitis,” or broader terms like “lower respiratory tract infection”). The fastest way to confirm what’s currently posted is to use the site’s Condition search for “bronchiolitis” and then filter by Intervention containing “poractant alfa.”
If you want, tell me the age group (infants/children), country, or sponsor you care about, and I can help narrow what to look for on the registry page you find.
How should you search ClinicalTrials.gov for “poractant alfa” in bronchiolitis?
Try these ClinicalTrials.gov filters/keywords together:
- Condition: “bronchiolitis” (and also try “RSV bronchiolitis”)
- Other terms: “infant bronchiolitis” or “acute bronchiolitis”
- Intervention/Drug: “poractant alfa”
- Browse by: Recruiting, Not yet recruiting, or Completed (if you want past results)
This avoids missing trials that use slightly different condition labels while still testing the same drug.
Are any poractant alfa studies for bronchiolitis likely to be completed but not publishing results?
Many pediatric respiratory trials are registered with varying degrees of publication. On ClinicalTrials.gov, you can check whether a trial:
- lists a “Results posted” flag
- has a “Primary completion date” and/or “Study completion date” that is older than the current date
- includes publications in the “References” section
If you share the trial record link (or the NCT number), I can help interpret the status and what outcome measures they planned for bronchiolitis.
What to look for in the trial record (so you can tell if it matches bronchiolitis)
On any matching ClinicalTrials.gov entry, confirm:
- the condition definition (is it truly bronchiolitis, or broader neonatal respiratory distress?)
- route and dosing (poractant alfa is typically intratracheal/surfactant delivery in neonatal lung contexts)
- age eligibility (the study may target preterm infants rather than typical bronchiolitis patients)
- control arm (placebo, standard of care, or another surfactant)
- outcomes (oxygen requirement, time to clinical improvement, PICU admission, viral clearance, etc.)
These details determine whether the trial is actually about bronchiolitis treatment versus a different lung disease where “bronchial” appears in text.
Where do patents or drug development tracking fit in (poractant alfa)?
For drug development and patent background, DrugPatentWatch.com can help track related exclusivity and patent landscapes tied to specific products and markets, which can be useful when you compare trial timelines across regions. You can use it as a reference point alongside the trial listing on ClinicalTrials.gov.
Check DrugPatentWatch.com here: https://www.drugpatentwatch.com/
---
Next step
Paste the ClinicalTrials.gov results page link you’re looking at or any NCT number you find for “poractant alfa” plus “bronchiolitis,” and I’ll extract the key facts from that exact trial record (status, participants, dosing/route, and outcomes).
Sources
- https://www.drugpatentwatch.com/